NCI-2025-02745

A Phase 1, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of IPH4502 as a Single Agent in Advanced Solid Tumors

This is a Phase 1 research study testing a new investigational drug called IPH4502 in people with advanced solid tumors—which means cancers that have spread or are no longer responding to standard treatments and affect solid organs like the lungs, liver, breast, or colon. IPH4502 is an experimental immunotherapy drug, meaning it’s designed to help the body’s immune system recognize and attack cancer cells. The study is open-label, which means that both the doctors and the patients know they are receiving IPH4502 — there's no placebo group

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06781983

Clinical Trial Site: Sinai

To see all available clinical trials click here.